EGFR and non-small cell lung carcinoma: Nowadays, EGFR-TKI has been administrated as a first-line treatment for NSCLC in stage IV with EGFR mutations, and it demonstrates a better efficacy compared to traditional chemotherapy in the selected patients.[4,5] Drugs are rapidly updated, in terms of EGFR-TKI, includes the first generation of gefitinib, erlotinib and icotinib, the second generation of afatinib, dacomitinib and the third generation of osimertinib.